Is Equillium, Inc. (EQ) a Buy, Sell, or Hold?
Equillium, Inc.
NASDAQ:EQ
$2.62 USD
-$0.14 (-5.07%)
- Volume
- 551.91K
- Average Volume
- 811.34K
- Market Capitalization
- $93.07M
- P/E Ratio
- -6.96
- Dividend Yield
- 0.00%
- Price Target
- $6.50
- Year High
- $3.54
- Year Low
- $0.36
- Day High
- —
- Day Low
- —
- Payout Ratio
- $0.00
- Current Ratio
- $18.62
Industry, Sector & symbol
| Stock Exchange | NASDAQ |
| CEO | Bruce D. Steel |
| Industry | Biotechnology |
| Sector | Healthcare |
| Current Symbol | EQ |
| CUSIP | 29446K106 |
| CIK | 0001746466 |
| Web | https://equilliumbio.com |
| Phone | 858 412 5302 |
| Currency | USD |
| Employees | 14 |
| Country | US |
Liquidity
| Debt-to-Equity Ratio | 0.01 |
| Payout Ratio | 0.00 |
| Current Ratio | 18.62 |
| Quick Ratio | 18.62 |
| Cash Ratio | 18.33 |
Sales & Book Value
| Annual Sales | $- |
| Price / Sales | 0.00 |
| Cash Flow | -0.20 |
| Price / Cash Flow | -4.92 |
| Price / Book | 4.24 |
Price Target and Rating
| Average Stock Price Forecast | $6.50 |
| High Stock Price Forecast | $7.00 |
| Low Stock Price Forecast | $5.00 |
| Forecast Upside/Downside | -59.69% |
| Consensus Rating | Sell |
| Rating Score(0-5) | 2 |
| Research Coverage | 12 Analysts |
Profitability
| EPS (Most Recent Fiscal Year) | $-0.39 |
| Trailing P/E Ratio | -6.96 |
| PEG Ratio | 0.22 |
| P/E Growth | 0.22 |
| Net Income | $-22.4M |
| Net Margin | 0.00% |
| Pretax Margin | 0.00% |
| Return on Equity | -61.43% |
| Return on Assets | -30.21% |
Financials Score
| AltmanZ Score | 10.26 |
| Piotroski Score | 2.00 |
| Working Capital | 58.93M |
| Total Assets | 63.08M |
| Ebit | -19.06M |
| Market Cap | 90.22M |
| Total Liabilities | 3.6M |
Poll Results
About Equillium, Inc. (NASDAQ:EQ) Stock
Equillium, Inc. is a clinical-stage biopharmaceutical company focused on developing and bringing to market products designed to address severe autoimmune and inflammatory (immuno-inflammatory) disorders where current treatment options are insufficient. The company's primary drug candidate is itolizumab (EQ001), a monoclonal antibody in clinical development that targets the novel CD6 immune checkpoint receptor. Itolizumab is currently in Phase III trials for acute graft-versus-host disease, has completed Phase Ib studies for asthma, and is also undergoing Phase Ib trials for lupus nephritis. In addition to itolizumab, Equillium is advancing EQ101 for the treatment of cutaneous T cell lymphoma and alopecia areata, and EQ102, which targets various gastrointestinal conditions. Headquartered in ... La Jolla, California, the company was incorporated in 2017 and previously operated as Attenuate Biopharmaceuticals, Inc. before changing its name to Equillium, Inc. in May 2017.
2026-06-18 08:00:00
Three-year renewal follows early campaign results that delivered up to 40% increases in average order value and nearly double the conversion rates using ClearLake TORONTO, ON / ACCESS Newswire / June 18, 2026 / EQ Inc. (TSXV:EQ.V) ("EQ Works" or the "Company"), a leader in AI and data-driven software and solutions that empowers brands to better understand, acquire, and retain their most valuable customers, today announced a three-year renewal and expansion of its partnership with a leading Canadian publisher, including the adoption of a SaaS license for its proprietary ClearLake platform. Under the expanded agreement, the publisher's internal teams will gain direct access to ClearLake to independently conduct advanced customer, competitor, and market research using EQ Works' proprietary data and analytics.
Equillium Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2026-06-02 16:05:00
LA JOLLA, Calif., June 02, 2026 (GLOBE NEWSWIRE) -- Equillium, Inc. (Nasdaq: EQ), a biotechnology innovator developing novel therapies to treat severe autoimmune and inflammatory disorders, today announced that on June 1, 2026, the Compensation Committee of Equillium's Board of Directors granted an inducement award consisting of nonstatutory stock options to purchase a total of 145,000 shares of common stock to a new employee under Equillium's 2024 Inducement Plan. The Compensation Committee approved the stock option as an inducement material to such employee's employment in accordance with Nasdaq Listing Rule 5635(c)(4).
2026-06-01 22:14:03
Equillium, Inc. (EQ) Discusses Mechanistic Insights Linking AhR Signaling and miR-124 in Inflammatory Disease Transcript
Equillium Links AhR Activation to miR-124 as EQ504 Heads Toward Phase 1
2026-05-29 11:05:23
Equillium NASDAQ: EQ Chief Scientific Officer Stephen Connelly outlined new preclinical data during a company webinar focused on the relationship between the aryl hydrocarbon receptor, or AhR, and miR-124, a microRNA implicated in inflammatory disease biology.
Equillium to Participate in the 2026 Jefferies Global Healthcare Conference
2026-05-28 16:05:00
LA JOLLA, Calif., May 28, 2026 (GLOBE NEWSWIRE) -- Equillium, Inc. (Nasdaq: EQ), a biotechnology innovator developing novel therapies to treat severe autoimmune and inflammatory disorders, today announced that management will participate in a fireside chat at the 2026 Jefferies Global Healthcare Conference on Wednesday, June 3, 2026 at 4:55pm EDT.
2026-05-20 16:05:00
LA JOLLA, Calif., May 20, 2026 (GLOBE NEWSWIRE) -- Equillium, Inc. (Nasdaq: EQ), a biotechnology innovator developing novel therapies to treat severe autoimmune and inflammatory disorders, today announced it will host a virtual investor event on Wednesday, May 27, 2026, at 11:00 AM ET.
Equillium Reports First Quarter 2026 Financial Results and Corporate Highlights
2026-05-13 16:01:00
Phase 1 proof-of-mechanism study of EQ504 on track to initiate in mid-2026, with data expected approximately six months thereafter
Equillium Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2026-05-01 16:42:00
LA JOLLA, Calif., May 01, 2026 (GLOBE NEWSWIRE) -- Equillium, Inc. (Nasdaq: EQ), a biotechnology innovator developing novel therapies to treat severe autoimmune and inflammatory disorders, today announced that on May 1, 2026, the Compensation Committee of Equillium's Board of Directors granted inducement awards consisting of nonstatutory stock options to purchase an aggregate of 800,000 shares of common stock to two new employees under Equillium's 2024 Inducement Plan. The Compensation Committee approved the stock option grants as an inducement material to such employees' employment in accordance with Nasdaq Listing Rule 5635(c)(4).
Frequently Asked Questions
-
What is the current Equillium, Inc. (EQ) stock price?
-
Equillium, Inc.(NASDAQ:EQ) stock price is $2.62 in the last trading session. During the trading session, EQ stock reached the peak price of $3.54 while $0.36 was the lowest point it dropped to. The percentage change in EQ stock occurred in the recent session was --5.07% while the dollar amount for the price change in EQ stock was -$-0.14.
-
EQ's industry and sector of operation?
-
The NASDAQ listed EQ is part of Biotechnology industry that operates in the broader Healthcare sector.
-
Who are the executives of EQ?
-
Snehal Naik | Chief Development Officer
Lisette Acevedo | Vice President of Clinical Development
Bruce D. Steel | Co-Founder, Chief Executive Officer & Director
Christine Zedelmayer | Senior Vice President & Chief Operating Officer
Penny Tom | Senior Vice President of Finance & Principal Accounting Officer -
How many employees does EQ have?
-
Number of EQ employees currently stands at 14. EQ operates from 2223 Avenida De La Playa, La Jolla, CA 92037, US.
-
Link for EQ official website?
-
Official Website of EQ is: https://equilliumbio.com
-
How do I contact EQ?
-
EQ could be contacted at phone #858 412 5302 and can also be accessed through its website. EQ operates from 2223 Avenida De La Playa, La Jolla, CA 92037, US.
-
How many shares of EQ are traded daily?
-
The average number of EQ shares traded daily for last 3 months was 811.34K.
-
What is the market cap of EQ currently?
-
The market value of EQ currently stands at $93.07M with its latest stock price at $2.62